Rosen Law Firm Investigates Tandem Diabetes Securities Claims

Written by Emily J. Thompson, Senior Investment Analyst

TNDM+3.4%

Source: PRnewswire

Updated: 2d ago

0mins

Source: PRnewswire

Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ:TNDM) for possibly issuing misleading business information, emphasizing its commitment to protecting investor rights.
Significant Stock Drop: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, indicating market concerns over the company's transparency.
Class Action Preparation: The firm is preparing a class action to recover investor losses, demonstrating its strong commitment to investor rights and attracting affected investors with a no upfront fee structure.
Firm's Reputation: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its leadership in the industry and robust support for investors.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like TNDM with instant alerts to capture every critical market movement.

Sign up for free to build your custom watchlist and receive professional-grade stock notifications.

TNDM

$19.76+Infinity%1D

Analyst Views on TNDM

Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 26.33 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

18 Analyst Rating

8 Buy

10 Hold

0 Sell

Moderate Buy

Current: 19.110

Low

14.00

Averages

26.33

High

55.00

Current: 19.110

Low

14.00

Averages

26.33

High

55.00

TD Cowen

Mathew Blackman

Buy

maintain

$25

2026-01-26

New

Reason

TD Cowen

Mathew Blackman

Price Target

$25

AI Analysis

2026-01-26

New

maintain

Buy

Reason

TD Cowen transferred coverage of Tandem Diabetes to analyst Mathew Blackman, who kept a Buy rating and raised the price target on the stock to $25. The firm called this a "differentiated call," and sees key drivers of stock performance, adding that Tandem is a "a story stock," but one it supports with "differentiated modeling and survey work."

Goldman Sachs

David Roman

Neutral

maintain

$16 -> $25

2026-01-09

Reason

Goldman Sachs

David Roman

Price Target

$16 -> $25

2026-01-09

maintain

Neutral

Reason

Goldman Sachs analyst David Roman raised the firm's price target on Tandem Diabetes to $25 from $16 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TNDM

Unlock Now

About TNDM

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.